Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Phase 1 Terminated 5 enrolled Indiana University Celgene Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with surgery.

Timeline

Start: 2011-05
Primary completion: 2012-12
Completion: 2014-03

Outcome

Outcome not reported

Stopped: “Treatment was ineffective”

Publications

Shahda S, Loehrer PJ, Clark RS, Spittler AJ, Althouse SK, Chiorean EG. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Oncologist. 2016 Jun;21(6):664-5. doi: 10.1634/theoncologist.2016-0071. Epub 2016 Jun 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenalidomide	Other / unclassified	10 mg	Oral
Subject	Lenalidomide	Other / unclassified	15 mg	Oral
Subject	Lenalidomide	Other / unclassified	20 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Subject	Sorafenib	Small molecule	400 mg	Oral